Jennifer Schmitke
Chief Operating Officer chez IMV INC.
Profil
Jennifer Schmitke is currently the Chief Operating Officer at IMV, Inc. She previously worked as a Senior Director at Biogen, Inc., SVP-Technical Operations & Quality at Epizyme, Inc., Vice President & Head-Program Management at Magenta Therapeutics, Inc., and Vice President at Omega Therapeutics, Inc. Schmitke received an undergraduate degree from Queen's University and a doctorate degree from Massachusetts Institute of Technology.
Postes actifs de Jennifer Schmitke
| Sociétés | Poste | Début |
|---|---|---|
| IMV INC. | Chief Operating Officer | - |
Anciens postes connus de Jennifer Schmitke
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | 01/04/2022 |
| BIOGEN INC. | Director/Board Member | - |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - |
Formation de Jennifer Schmitke
| Queen's University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| IMV INC. | Health Technology |
| OMEGA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
